Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment

Eli Lilly and Company (LLY) and Incyte (INCY) announced positive topline results from the late-stage study of baricitinib for the treatment of adults with severe alopecia areata (AA), an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress.